Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies

INTRODUCTION: Biosimilar CT-P13 was approved with limited data from clinical trials compared to the originator infliximab in biologic-naïve patients with rheumatoid arthritis. Three prospective post-marketing surveillance studies have been conducted in Japanese biologic-naïve patients and switched p...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Nishikawa, Kiyohiro, Yamada, Fumika, Morita, Akimichi, Ohtsuki, Mamitaro, Suzuki, Yasuo, Watanabe, Mamoru, Yamanaka, Hisashi, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584739/
https://www.ncbi.nlm.nih.gov/pubmed/37700154
http://dx.doi.org/10.1007/s40264-023-01340-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584739/
https://www.ncbi.nlm.nih.gov/pubmed/37700154
http://dx.doi.org/10.1007/s40264-023-01340-1

Ejemplares similares